Eqis Capital Management, Inc. Innoviva, Inc. Transaction History

Eqis Capital Management, Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$14.4 - $16.4 $169,084 - $192,568	11,742 New	11,742 $192,000
Q2 2022 Aug 08, 2022	BUY	$14.32 - $19.88 $183,038 - $254,106	12,782 New	12,782 $188,000
Q1 2022 May 16, 2022	SELL	$15.39 - $20.25 $221,585 - $291,559	-14,398 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$15.91 - $18.72 $229,072 - $269,530	14,398 New	14,398 $248,000

227

78.9M

37.6K

300

Ticker INVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 69,706,000
Market Cap $1.24B
Description
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a ...

Get notified when there are updates to the investment portfolio of Eqis Capital Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Eqis Capital Management, Inc. with notifications on news.